{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:57:10Z","timestamp":1767146230676,"version":"build-2238731810"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ejcped.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EJC Paediatric Oncology"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.ejcped.2022.100002","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T20:16:29Z","timestamp":1671826589000},"page":"100002","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Safety of mRNA-based COVID-19 vaccination in paediatric patients with a PEG-asparaginase allergy"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1765-6984","authenticated-orcid":false,"given":"Nancy","family":"Broos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leiah J.","family":"Brigitha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemieke","family":"Schuurhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike","family":"R\u00f6ckmann-Helmbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9101-507X","authenticated-orcid":false,"given":"Wim J.E.","family":"Tissing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Pieters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge M.","family":"van der Sluis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marike B.","family":"Stadermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejcped.2022.100002_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29005","article-title":"Clinical presentations and outcomes of children with cancer and COVID-19: a systematic review","volume":"68","author":"Meena","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ejcped.2022.100002_bib2","unstructured":"World Health Organization. Coronavirus Disease (COVID-19), website: Coronavirus (who.int), checked on the 01-03-2022."},{"key":"10.1016\/j.ejcped.2022.100002_bib3","unstructured":"European Medicine Agency. Summary of Product Characteristics Comirnaty (COVID-19 mRNA Vaccine from Pfizer-BioNTech), website: Comirnaty, INN-COVID-19 mRNA Vaccine (nucleoside-modified) (europa.eu), checked on 02-03-2022."},{"key":"10.1016\/j.ejcped.2022.100002_bib4","unstructured":"European Medicine Agency. Summary of Product Characteristics Spikevax (COVID-19 mRNA Vaccine from Moderna), website: Spikevax, INN-COVID-19 mRNA Vaccine (nucleoside modified); (europa.eu), checked on 02-03-2022."},{"issue":"5","key":"10.1016\/j.ejcped.2022.100002_bib5","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jaip.2018.12.003","article-title":"Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized","volume":"7","author":"Stone","year":"2019","journal-title":"Clin Immunol Pract"},{"key":"10.1016\/j.ejcped.2022.100002_bib6","unstructured":"European Medicines Agency. COVID-19 Vaccines: Authorized, website: COVID-19 vaccines: authorised | European Medicines Agency (europa.eu), checked on 04-06-2022."},{"key":"10.1016\/j.ejcped.2022.100002_bib7","unstructured":"Food and Drug Administration. COVID-19 Vaccines, website: COVID-19 Vaccines | FDA, checked on 04-06-2022."},{"key":"10.1016\/j.ejcped.2022.100002_bib8","series-title":"PROTOCOL ALL-11 Treatment Study Protocol of the Dutch Childhood Oncology Group for Children and Adolescents (1-19 Year) with Newly Diagnosed Acute Lymphoblastic Leukemia","year":"2018"},{"key":"10.1016\/j.ejcped.2022.100002_bib9","unstructured":"European Medicine Agency. Summary of Product Characteristics Oncaspar, website: , checked on 02-03-2022."},{"key":"10.1016\/j.ejcped.2022.100002_bib10","doi-asserted-by":"crossref","first-page":"65e75","DOI":"10.1016\/j.ejca.2021.11.016","article-title":"Hypersensitivity to Pegylated E.coli asparaginase as first line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group","volume":"162","author":"Brigitha","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejcped.2022.100002_bib11","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1080\/10428194.2017.1397658","article-title":"Severe pegasparaginase hypersensitivity reaction rates (>= grade 3) with intravenous infusion versus intramuscular injfection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials","volume":"59","author":"Burke","year":"2018","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.ejcped.2022.100002_bib12","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/bjh.16254","article-title":"Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker","volume":"189","author":"Kloos","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejcped.2022.100002_bib13","unstructured":"Dutch Centre for Infectious Disease Control (RIVM). COVID-19 Vaccination, version: 28-02-2022. Website: COVID-19-vaccinatie | LCI richtlijnen (rivm.nl), checked on: 02-03-2022."},{"issue":"13","key":"10.1016\/j.ejcped.2022.100002_bib14","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2013-10-534347","article-title":"A\u00a0prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia","volume":"123","author":"Tong","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejcped.2022.100002_bib15","series-title":"Common Terminology Criteria for Adverse Events (CTCAE)","year":"2017"},{"key":"10.1016\/j.ejcped.2022.100002_bib16","article-title":"mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegasparaginase","author":"Anvari","year":"2022101322","journal-title":"J.\u00a0Allergy Clin. Immunol. Pract."},{"issue":"2","key":"10.1016\/j.ejcped.2022.100002_bib17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jaip.2021.11.025","article-title":"The safety of SARS-CoV-2 vaccines in persons with a known history of pegasparaginase allergy: a single institution experience","volume":"10","author":"Rush","year":"2021","journal-title":"J.\u00a0Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.ejcped.2022.100002_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29295","article-title":"Safety of aministration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youth and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase","author":"Mark","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ejcped.2022.100002_bib19","series-title":"Oncologist Counseling Practice and COVID-19 Vaccination Outcomes for Patients with History of Pegasparaginase Hypersensitivity","author":"Zarnegar-Lumley","year":"2022"},{"issue":"23","key":"10.1016\/j.ejcped.2022.100002_bib20","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.18.02439","article-title":"Antibodies predict pegaspargase allergic reactions and failure of rechallenge","volume":"37","author":"Liu","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejcped.2022.100002_bib21","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1111\/all.14794","article-title":"Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation","volume":"76","author":"Klimek","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.ejcped.2022.100002_bib22","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1111\/all.15241","article-title":"Allergies and COVID-19 vaccines: an ENDA-EAACI position paper","volume":"77","author":"Babaud","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.ejcped.2022.100002_bib23","doi-asserted-by":"crossref","unstructured":"Tsujimura Y, Obata K, Mukai K, Shindou H, Yoshida M, Nishikado H, et\u00a0al. Basophils play a pivotal role in immunoglobulin-G-mediated but not immunoglobulin-E-mediated systemic anaphylaxis. Immunity 2008:28(4):581\u2013589.","DOI":"10.1016\/j.immuni.2008.02.008"},{"key":"10.1016\/j.ejcped.2022.100002_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2021.715844","article-title":"Anaphylaxis to pfizer\/BioNTech mRNA COVID-19 vaccine in a patient with clinically confirmed PEG allergy","volume":"2","author":"McSweeney","year":"2021","journal-title":"Frontiers in Allergy"},{"issue":"9","key":"10.1016\/j.ejcped.2022.100002_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.25524","article-title":"Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system","volume":"4","author":"Warren","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"6","key":"10.1016\/j.ejcped.2022.100002_bib26","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/jcph.1824","article-title":"PEG that reaction: a case series of allergy to polyethylene glycol","volume":"61","author":"Cox","year":"2021","journal-title":"J.\u00a0Clin. Pharmacol."}],"updated-by":[{"DOI":"10.1016\/j.ejcped.2025.100231","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000}}],"container-title":["EJC Paediatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772610X22000022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772610X22000022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T11:51:21Z","timestamp":1757418681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772610X22000022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":26,"alternative-id":["S2772610X22000022"],"URL":"https:\/\/doi.org\/10.1016\/j.ejcped.2022.100002","relation":{},"ISSN":["2772-610X"],"issn-type":[{"value":"2772-610X","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of mRNA-based COVID-19 vaccination in paediatric patients with a PEG-asparaginase allergy","name":"articletitle","label":"Article Title"},{"value":"EJC Paediatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejcped.2022.100002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100002"}}